Internal Medicine, Pulmonary Disease · Dallas, TX
NPI
1841243664
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
5939 Harry Hines
Dallas, TX, 75390
Phone (215) 645-5505
Groups this clinician bills Medicare through
Medicare paid, 2024
$23K
341 services
Medicare patients, 2024
194
Average age 71
Drug cost, 2024
$4.6M
1,106 prescriptions
Company payments, 2025
$8,810
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kelly Chin was code 94618 (pulmonary function testing), 112 times for 105 patients. In total Kelly Chin billed 341 services in 13 codes, and Medicare paid $23K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-05-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 94618 Pulmonary Function Testing | Office | 112 | 105 | $15.55 | $1,742 |
| 99233 Hospital E&M - Subsequent | Facility | 89 | 34 | $90.32 | $8,039 |
| 99214 Office E&M - Established | Office | 41 | 35 | $73.74 | $3,023 |
| 99215 Office E&M - Established | Office | 13 | 13 | $100.57 | $1,307 |
| 99223 Hospital E&M - Initial | Facility | 13 | 12 | $123.19 | $1,602 |
| 99213 Office E&M - Established | Office | 12 | 11 | $54.09 | $649 |
By year: 2022 $27K for 391 services; 2023 $24K for 343 services; 2024 $23K for 341 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kelly Chin prescribed most often to Medicare patients was Opsumit (Macitentan), with 208 prescriptions and refills. In total Kelly Chin wrote 1,106 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Opsumit Macitentan | 208 | 208 | 28 | $2.6M |
| Tadalafil Generic | 114 | 122 | 15 | $80K |
| Sildenafil Citrate Generic | 95 | 129 | 16 | $12K |
| Spironolactone Generic | 86 | 172 | 22 | $1,482 |
| Ambrisentan Generic | 68 | 68 | Under 11 | $180K |
| Furosemide Generic | 66 | 163 | 22 | $820 |
| Warfarin Sodium Generic | 62 | 162 | 24 | $934 |
| Potassium Chloride Generic | 51 | 99 | 13 | $5,336 |
| Winrevair Sotatercept-Csrk | 28 | 28 | Under 11 | $399K |
| Bosentan Generic | 27 | 27 | Under 11 | $43K |
| Torsemide Generic | 25 | 43 | Under 11 | $793 |
| Uptravi Selexipag | 21 | 21 | Under 11 | $492K |
| Adempas Riociguat | 20 | 20 | Under 11 | $269K |
| Eplerenone Generic | 19 | 31 | Under 11 | $2,887 |
| Eliquis Apixaban | 16 | 18 | Under 11 | $9,287 |
Brand drugs: - claims; generic drugs: 755 claims; opioid claims: 11.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kelly Chin $8,810 ($4,685 in general payments such as food, travel and fees and $4,125 for research) from 5 companies. The largest payer was United Therapeutics Corporation with $6,271.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.